Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A simple finger-prick blood test could help prevent unnecessary prescribing of antibiotics for people with the lung condition chronic obstructive pulmonary disease (COPD), according to a new study by researchers from Cardiff University, University of Oxford and King’s College London.

None © Shutterstock

With funding from the National Institute for Health Research, the team demonstrated that using a CRP finger-prick blood test resulted in 20% fewer people using antibiotics for COPD flare-ups. Importantly, this reduction in antibiotic use did not have a negative effect on patients’ recovery over the first two weeks after their consultation at their GP surgery, or on their well-being or use of health care services over the following six months.

Safely reducing the use of antibiotics in this way may help in the battle against antibiotic resistance.

Read more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.